Related People
Paris – Mayer Brown advised the SERB group, a global specialty pharmaceutical group, on the structuring of the acquisition of the exclusive US rights to bentracimab, a ticagrelor reversal agent, from SFJ Pharmaceuticals, a global drug development company.
Mayer Brown advised SERB Pharmaceuticals on the structuring of the acquisition with a team composed of Partner Olivier Parawan, Associates Sarah Rahmoun and Julia Videau in Paris and Partner Remmelt Reigersman in San Francisco.
Mayer Brown advised SERB Pharmaceuticals on the structuring of the acquisition with a team composed of Partner Olivier Parawan, Associates Sarah Rahmoun and Julia Videau in Paris and Partner Remmelt Reigersman in San Francisco.
Media Contacts
-
Public Relations Contacts
Business Development/Marketing-Communication Manager
News
-
September 202023
Stay up-to-date on our perspectives
Subscribe to Email